Prognostic factors and outcomes in metastatic uveal melanoma treated with PD-1 or combined PD-1 / CTLA-4 inhibition
Markus V. Heppt(Universitätsklinikum Erlangen), Carola Berking(Universitätsklinikum Erlangen), Rudolf Herbst(Helios Klinikum Erfurt), Julia K. Tietze(LMU Klinikum), Markus Meißner(Goethe University Frankfurt), Daniela Goeppner, Sebastian Haferkamp(University Hospital Regensburg), Andrea Forschner(University of Tübingen), David Rafei‐Shamsabadi(University Medical Center Freiburg), C. Schmid-Tannwald(LMU Klinikum), P. Terheyden(University Hospital Schleswig-Holstein), Friedegund Meier(National Center for Tumor Diseases), Katharina C. Kaehler(Christian-Albrechts-Universität zu Kiel), Michael Constantin Kirchberger(Friedrich-Alexander-Universität Erlangen-Nürnberg), Thomas Eigentler(University Children's Hospital Tübingen), Irmgard Bumeder(LMU Klinikum), Carmen Loquai(Johannes Gutenberg University Mainz), Mirjana Ziemer(University Medical Center), Constance Pfeiffer, Felix Kiecker(Humboldt-Universität zu Berlin), Beatrice Schell(SRH Wald-Klinikum Gera), Lucie Heinzerling(Ludwig-Maximilians-Universität München), Jochen Utikal(German Cancer Research Center), Margit A. Huber(Universität Ulm), S. Schd-Trcka
Journal Der Deutschen Dermatologischen Gesellschaft
January 1, 2017
Cited by 0
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression
|Journal of Clinical Investigation|2004|837